Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant-‐Tuberculosis (MDR-TB)

Trial Profile

Prospective, Randomized, Open Label Phase 3 Study of the Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin for Treatment of Patients With Fluoroquinolone-susceptible Multidrugresistant-‐Tuberculosis (MDR-TB)

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Delamanid (Primary) ; Levofloxacin (Primary) ; Linezolid (Primary) ; Pyrazinamide (Primary)
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Acronyms DAZZLE
  • Most Recent Events

    • 01 Dec 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top